New Products

See allHide authors and affiliations

Science  20 Oct 2017:
Vol. 358, Issue 6361, pp. 394
DOI: 10.1126/science.358.6361.394

FFPE DNA Repair Mix

The SureSeq FFPE DNA Repair Mix is optimized to repair a broad range of damage in formalin-fixed, paraffin-embedded (FFPE)–derived DNA. Fixation processes significantly damage nucleic acids, and long storage times can produce problematic artifacts. In addition, many FFPE samples are often irreplaceable, and there is a real need to reduce DNA input for NGS. On the other hand, hybridization-based approaches eliminate PCR bias—providing much more reliable data—but require higher DNA inputs. The SureSeq mix increases the success and accuracy of hybridization-based NGS for FFPE samples by repairing damage such as nicks and gaps, oxidized bases, blocked 3' ends, and deamination of cytosine to uracil. Repairing this damage enables reduction of the amount of required starting material down to as little as 100 ng, while delivering excellent sequencing data for the utmost confidence in variant calling.

  • Oxford Gene Technology

  • For info: +44-(0)-1865-856826

  • www.ogt.com

Liquid Biopsy Kit

TruePrime LB addresses current liquid biopsy sensitivity and specificity issues by using adapted amplification of cancer-specific, large-fragment, cell-free DNA based on primer-free technology that combines the enzymes TthPrimPol and Phi29 DNA polymerase. TruePrime-mediated circulating tumor DNA amplification specifically selects the larger, more cancer-specific DNA fragment-size population from human plasma. Consequently, TruePrime LB provides a method for assessing cancer genome information from all patients, regardless of tumor burden, with superior sensitivity and specificity. The kit also preserves the single-nucleotide variants (SNVs) and SNV frequencies across different sequencing technologies and allows the amplification of cell-free DNA to levels that permit sequencing. TruePrime LB offers a screening method for de novo detection of cancer or reoccurrence of cancer based on a threshold of amplified DNA obtainable within a certain reaction time frame.

Lung Cancer FISH Probes

The IQFISH panel for lung cancer is a set of oligonucleotide-based FISH probes, premixed with IQFISH Buffer, for the detection of rearrangements involving the ALK, ROS, and RET genes, and the detection of MET gene amplification by fluorescence in situ hybridization (FISH). These probes are to be used on lung paraffin-embedded tissue sections. Non–small cell lung cancer may involve genetic aberrations that can be used to direct therapy. For example, a fusion of ALK with EML4 occurs in about 5% of cancers and is linked to strong patient response to treatment with crizotinib. Fusions of ROS1 and RET or amplification of MET are also observed with potential treatment indication. Identification of these abnormalities is often done using FISH. This panel combines new generations of FISH technologies, pairing oligonucleotide-based SureFISH technology with a ready-to-use formulation of formamide-free IQ Hybridization Buffer, resulting in high signal-to-noise ratios with less than 4 hours of turnaround time.

cfDNA Extraction Kit

The AMS Biotechnology cfPure DNA Extraction Kit provides an automation-friendly method to obtain maximal circulating cell-free DNA (cfDNA) recovery from various specimen types, including fresh or frozen serum or plasma as well as plasma from blood collected in Streck Cell-Free DNA collection tubes. The cfPure system uses silica-coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma. The kit's optimized buffers ensure efficient recovery of cfDNA fragments from 100 bp–500 bp. Recovered DNA is suitable for numerous downstream applications, including bisulfite sequencing, NGS, and quantitative PCR. Recently, DNA shed from tumor cells has been identified as a noninvasive method of screening biomarkers for the early diagnosis and prognosis of cancer. This method, sometimes called "liquid biopsy," can provide guidance for treatment decisions, monitoring of cancer therapy, and organism-wide screening for the presence of nascent metastatic tumors in drug-treated cancer patients.

Liquid Biopsy Tests

GATC Biotech has expanded its liquid biopsy service with GATCLIQUID ONCOTARGET. A simple blood draw enables sensitive detection of blood cancers, such as acute myeloid leukemia and myeloproliferative neoplasms, in addition to melanoma, lung, colorectal, and pancreatic cancers, through analysis of actionable mutations in circulating tumor DNA. The service profiles 12 cancer genomic alterations so far. The continuously expanding target list makes GATCLIQUID ONCOTARGET suitable for detection and regular monitoring of various cancers that are difficult to characterize with conventional diagnostic procedures. Clinical researchers can explore, screen, and monitor a wide range of tumor-related mutations for close surveillance of tumor dynamics and cancer heterogeneity in individual patients. This droplet-digital PCR test detects genomic alterations with a sensitivity as low as 0.1%. Proprietary workflows and cutting-edge technologies enable quantification of low-level mutations during treatment as well as detection of cancer recurrence, often prior to clinical progression.

Flow Cytometry Antibodies

CapricoBiotechnology's high-quality fluorescent labeled antibodies are used for cellular immunophenotyping in clinical diagnosis, immunotherapy monitoring, and clinical trials. Immunophenotyping—a laboratory procedure used to study the proteins expressed by cells—is very commonly used in basic science research as well as in laboratory diagnostic testing. It can be done on tissue sections (fresh or fixed tissue), cell suspensions, and so on. We offer a number of immunophenotyping kits to evaluate the efficacy of any immunotherapy against cancer (e.g., CD3-, CD117-, CD71-, and CD25-expressing cells) and to determine CD4 expression by T cells and macrophages in HIV-infected patients after highly active antiretroviral therapy (HAART). Our R&D team is developing additional immunophenotyping kits for diagnosing the status of blood cancer (e.g., CD117-, CD71-, and CD25-expressing cells) and also for use with a cocktail of antibodies to quantify the number of CD4+ T cells per mL of blood for AIDS diagnosis.

  • Electronically submit your new product description or product literature information! Go to www.sciencemag.org/products/newproducts.dtl for more information.

  • Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are featured in this space. Emphasis is given to purpose, chief characteristics, and availabilty of products and materials. Endorsement by Science or AAAS of any products or materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.

Navigate This Article